Privia Health Group, Inc. (NASDAQ:PRVA) Shares Sold by US Bancorp DE

US Bancorp DE lessened its holdings in Privia Health Group, Inc. (NASDAQ:PRVA) by 12.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,924 shares of the company’s stock after selling 2,419 shares during the quarter. US Bancorp DE’s holdings in Privia Health Group were worth $308,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PRVA. Vanguard Group Inc. lifted its holdings in Privia Health Group by 1.1% in the first quarter. Vanguard Group Inc. now owns 11,400,035 shares of the company’s stock valued at $223,327,000 after acquiring an additional 121,701 shares during the period. Millennium Management LLC lifted its stake in shares of Privia Health Group by 2,994.2% in the 2nd quarter. Millennium Management LLC now owns 1,138,526 shares of the company’s stock valued at $19,788,000 after purchasing an additional 1,101,730 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Privia Health Group by 18.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,118,619 shares of the company’s stock valued at $19,441,000 after purchasing an additional 173,934 shares during the last quarter. First Light Asset Management LLC acquired a new position in Privia Health Group during the 1st quarter worth about $21,620,000. Finally, Bellevue Group AG lifted its stake in Privia Health Group by 0.7% during the 1st quarter. Bellevue Group AG now owns 1,059,171 shares of the company’s stock worth $20,749,000 after acquiring an additional 7,475 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on PRVA. KeyCorp began coverage on Privia Health Group in a report on Friday, October 11th. They set an “overweight” rating and a $23.00 price target on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $28.00 price target on shares of Privia Health Group in a report on Wednesday, August 14th. Robert W. Baird raised their price objective on Privia Health Group from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Monday, August 26th. Barclays raised their price objective on Privia Health Group from $19.00 to $21.00 and gave the company an “equal weight” rating in a research note on Friday, November 8th. Finally, Truist Financial raised their price target on Privia Health Group from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Privia Health Group has an average rating of “Buy” and a consensus price target of $25.07.

Privia Health Group Trading Down 1.0 %

NASDAQ PRVA opened at $22.58 on Wednesday. The stock’s 50 day moving average is $18.48 and its two-hundred day moving average is $18.39. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of 225.80, a PEG ratio of 4.84 and a beta of 0.76. Privia Health Group, Inc. has a 1-year low of $15.92 and a 1-year high of $24.35.

Insider Activity

In other Privia Health Group news, CEO Parth Mehrotra sold 135,142 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $18.50, for a total transaction of $2,500,127.00. Following the completion of the sale, the chief executive officer now owns 247,771 shares in the company, valued at approximately $4,583,763.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 14.20% of the stock is currently owned by corporate insiders.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.